Literature DB >> 28286193

In Children With Nonalcoholic Fatty Liver Disease, Zone 1 Steatosis Is Associated With Advanced Fibrosis.

Jonathan A Africa1, Cynthia A Behling2, Elizabeth M Brunt3, Nan Zhang4, Yunjun Luo4, Alan Wells5, Jiayi Hou5, Patricia H Belt6, Rohit Kohil7, Joel E Lavine8, Jean P Molleston9, Kimberly P Newton1, Peter F Whitington10, Jeffrey B Schwimmer11.   

Abstract

BACKGROUND & AIMS: Focal zone 1 steatosis, although rare in adults with nonalcoholic fatty liver disease (NAFLD), does occur in children with NAFLD. We investigated whether focal zone 1 steatosis and focal zone 3 steatosis are distinct subphenotypes of pediatric NAFLD. We aimed to determine associations between the zonality of steatosis and demographic, clinical, and histologic features in children with NAFLD.
METHODS: We performed a cross-sectional study of baseline data from 813 children (age <18 years; mean age, 12.8 ± 2.7 years). The subjects had biopsy-proven NAFLD and were enrolled in the Nonalcoholic Steatohepatitis Clinical Research Network. Liver histology was reviewed using the Nonalcoholic Steatohepatitis Clinical Research Network scoring system.
RESULTS: Zone 1 steatosis was present in 18% of children with NAFLD (n = 146) and zone 3 steatosis was present in 32% (n = 244). Children with zone 1 steatosis were significantly younger (10 vs 14 years; P < .001) and a significantly higher proportion had any fibrosis (81% vs 51%; P < .001) or advanced fibrosis (13% vs 5%; P < .001) compared with children with zone 3 steatosis. In contrast, children with zone 3 steatosis were significantly more likely to have steatohepatitis (30% vs 6% in children with zone 1 steatosis; P < .001).
CONCLUSIONS: Children with zone 1 or zone 3 distribution of steatosis have an important subphenotype of pediatric NAFLD. Children with zone 1 steatosis are more likely to have advanced fibrosis and children with zone 3 steatosis are more likely to have steatohepatitis. To achieve a comprehensive understanding of pediatric NAFLD, studies of pathophysiology, natural history, and response to treatment should account for the zonality of steatosis.
Copyright © 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Disease Progression; NASH; Obesity; Pediatric

Mesh:

Year:  2017        PMID: 28286193      PMCID: PMC5589478          DOI: 10.1016/j.cgh.2017.02.030

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  24 in total

1.  Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.

Authors:  Brent A Neuschwander-Tetri; Jeanne M Clark; Nathan M Bass; Mark L Van Natta; Aynur Unalp-Arida; James Tonascia; Claudia O Zein; Elizabeth M Brunt; David E Kleiner; Arthur J McCullough; Arun J Sanyal; Anna Mae Diehl; Joel E Lavine; Naga Chalasani; Kris V Kowdley
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

Review 2.  Zonation of hepatic fatty acid metabolism - The diversity of its regulation and the benefit of modeling.

Authors:  J Schleicher; C Tokarski; E Marbach; M Matz-Soja; S Zellmer; R Gebhardt; S Schuster
Journal:  Biochim Biophys Acta       Date:  2015-02-09

3.  Zonation of fatty acid metabolism in rat liver.

Authors:  M Guzmán; J Castro
Journal:  Biochem J       Date:  1989-11-15       Impact factor: 3.857

Review 4.  Liver zonation: Novel aspects of its regulation and its impact on homeostasis.

Authors:  Rolf Gebhardt; Madlen Matz-Soja
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

5.  Role for hedgehog signaling in hepatic stellate cell activation and viability.

Authors:  Jason K Sicklick; Yin-Xiong Li; Steve S Choi; Yi Qi; Wei Chen; Marcia Bustamante; Jiawen Huang; Marzena Zdanowicz; Terese Camp; Michael S Torbenson; Marcos Rojkind; Anna Mae Diehl
Journal:  Lab Invest       Date:  2005-11       Impact factor: 5.662

6.  Subcellullar localization, developmental expression and characterization of a liver triacylglycerol hydrolase.

Authors:  R Lehner; Z Cui; D E Vance
Journal:  Biochem J       Date:  1999-03-15       Impact factor: 3.857

7.  β-Catenin regulates hepatic mitochondrial function and energy balance in mice.

Authors:  Nadja Lehwald; Guo-Zhong Tao; Kyu Yun Jang; Ioanna Papandreou; Bowen Liu; Bo Liu; Marybeth A Pysz; Jürgen K Willmann; Wolfram T Knoefel; Nicholas C Denko; Karl G Sylvester
Journal:  Gastroenterology       Date:  2012-06-07       Impact factor: 22.682

8.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

9.  Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver disease.

Authors:  Christine Carter-Kent; Elizabeth M Brunt; Lisa M Yerian; Naim Alkhouri; Paul Angulo; Rohit Kohli; Simon C Ling; Stavra A Xanthakos; Peter F Whitington; Phunchai Charatcharoenwitthaya; Jason Yap; Rocio Lopez; Arthur J McCullough; Ariel E Feldstein
Journal:  J Pediatr Gastroenterol Nutr       Date:  2011-02       Impact factor: 2.839

10.  Hedgehog pathway and pediatric nonalcoholic fatty liver disease.

Authors:  Marzena Swiderska-Syn; Ayako Suzuki; Cynthia D Guy; Jeffrey B Schwimmer; Manal F Abdelmalek; Joel E Lavine; Anna Mae Diehl
Journal:  Hepatology       Date:  2013-04-01       Impact factor: 17.425

View more
  23 in total

1.  Clinical and Pathological Risk Factors Associated with Liver Fibrosis and Steatosis in African-Americans with Chronic Hepatitis C.

Authors:  Ali Afsari; Edward Lee; Babak Shokrani; Tina Boortalary; Zaki A Sherif; Mehdi Nouraie; Adeyinka O Laiyemo; Kawtar Alkhalloufi; Hassan Brim; Hassan Ashktorab
Journal:  Dig Dis Sci       Date:  2017-06-13       Impact factor: 3.199

Review 2.  Epidemiology of Pediatric Nonalcoholic Fatty Liver Disease.

Authors:  Elizabeth L Yu; Jeffrey B Schwimmer
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-04-13

3.  An update on the role of the microbiome in non-alcoholic fatty liver disease pathogenesis, diagnosis, and treatment.

Authors:  Marialena Mouzaki; Rohit Loomba
Journal:  Curr Treat Options Gastroenterol       Date:  2020-05-02

Review 4.  The Genetics of Pediatric Nonalcoholic Fatty Liver Disease.

Authors:  Nidhi P Goyal; Jeffrey B Schwimmer
Journal:  Clin Liver Dis       Date:  2017-10-05       Impact factor: 6.126

Review 5.  Recent advances in the epidemiology of nonalcoholic fatty liver disease in children.

Authors:  Warren L Shapiro; Sheila L Noon; Jeffrey B Schwimmer
Journal:  Pediatr Obes       Date:  2021-09-09       Impact factor: 4.000

6.  Do Zones of Hepatic Steatosis Associate With Subtypes and Progression of Nonalcoholic Fatty Liver Disease in Children?

Authors:  Veeral Ajmera; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2017-12-02       Impact factor: 11.382

7.  Severe obesity is associated with liver disease severity in pediatric non-alcoholic fatty liver disease.

Authors:  Aradhna Seth; Sarah Orkin; Toshifumi Yodoshi; Chunyan Liu; Lin Fei; Jennifer Hardy; Andrew T Trout; Ana-Catalina Arce Clachar; Kristin Bramlage; Stavra Xanthakos; Marialena Mouzaki
Journal:  Pediatr Obes       Date:  2019-10-27       Impact factor: 4.000

8.  Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease.

Authors:  Miriam B Vos; Lara Dimick-Santos; Ruby Mehta; Stephanie O Omokaro; Johannes Taminiau; Elmer Schabel; David E Kleiner; Peter Szitanyi; Piotr Socha; Jeffrey B Schwimmer; Stephanie Noviello; Debra G Silberg; Richard Torstenson; Veronica Miller; Joel E Lavine
Journal:  Gastroenterology       Date:  2019-09-12       Impact factor: 22.682

Review 9.  Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD - Reconciling the present with the past.

Authors:  Oyekoya T Ayonrinde
Journal:  JHEP Rep       Date:  2021-02-26

10.  Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality.

Authors:  Tracey G Simon; Bjorn Roelstraete; Kayla Hartjes; Uzma Shah; Hamed Khalili; Henrik Arnell; Jonas F Ludvigsson
Journal:  J Hepatol       Date:  2021-07-03       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.